Article
Multidisciplinary Sciences
Karin Schmelz, Joern Toedling, Matt Huska, Maja C. Cwikla, Louisa-Marie Kruetzfeldt, Jutta Proba, Peter F. Ambros, Inge M. Ambros, Sengul Boral, Marco Lodrini, Celine Y. Chen, Martin Burkert, Dennis Guergen, Annabell Szymansky, Kathy Astrahantseff, Annette Kuenkele, Kerstin Haase, Matthias Fischer, Hedwig E. Deubzer, Falk Hertwig, Patrick Hundsdoerfer, Anton G. Henssen, Roland F. Schwarz, Johannes H. Schulte, Angelika Eggert
Summary: Authors analyzed multi-region patient samples in neuroblastoma using genomics and transcriptomics, revealing temporal and spatial heterogeneity and questioning the reliability of single-biopsy based diagnostics.
NATURE COMMUNICATIONS
(2021)
Article
Biology
Mehran Makvandi, Minu Samanta, Paul Martorano, Hwan Lee, Sarah B. Gitto, Khushbu Patel, David Groff, Jennifer Pogoriler, Daniel Martinez, Aladdin Riad, Hannah Dabagian, Michael Zaleski, Tara Taghvaee, Kuiying Xu, Ji Youn Lee, Catherine Hou, Alvin Farrel, Vandana Batra, Sean D. Carlin, Daniel J. Powell, Robert H. Mach, Daniel A. Pryma, John M. Maris
Summary: The efficacy and toxicity of the PARP inhibitor parthanatine, radiolabeled with the alpha particle emitter astatine-211, in 11 patient derived neuroblastoma murine xenografts is investigated.
COMMUNICATIONS BIOLOGY
(2022)
Article
Mathematics, Interdisciplinary Applications
Yuxuan Dai, Chenhui Yu
Summary: This paper investigates a financial risk early-warning model based on financial data of listed companies in China's A-share information technology industry, and applies this model to Neusoft Group. The research results show that the model can better predict the financial risk of Neusoft Group.
Article
Oncology
Meredith S. Irwin, Arlene Naranjo, Fan F. Zhang, Susan L. Cohn, Wendy B. London, Julie M. Gastier-Foster, Nilsa C. Ramirez, Ruthann Pfau, Shalini Reshmi, Elizabeth Wagner, Jed Nuchtern, Shahab Asgharzadeh, Hiroyuki Shimada, John M. Maris, Rochelle Bagatell, Julie R. Park, Michael D. Hogarty
Summary: A revised neuroblastoma risk classifier incorporating INRGSS and SCAs has been validated, which may impact clinical trial eligibility and treatment assignment.
JOURNAL OF CLINICAL ONCOLOGY
(2021)
Article
Multidisciplinary Sciences
Weronika Przybyla, Kirsti Marie Gjersvoll Paulsen, Charitra Kumar Mishra, Stale Nygard, Solveig Engebretsen, Ellen Ruud, Gunhild Troen, Klaus Beiske, Lars Oliver Baumbusch
Summary: Neuroblastoma (NBL) is a deadly cancer in children with high genetic heterogeneity. This study used whole exome sequencing to identify known and novel gene variants associated with NBL. Additionally, genes involved in biological adhesion, neurological cell-cell adhesion, and immune response were identified. These findings provide valuable insights into the pathogenesis and clinical course of high-risk NBL.
Article
Oncology
John Thomas Lucas, Daniel Victor Wakefield, Michael Doubrovin, Yimei Li, Teresa Santiago, Sara Michele Federico, Thomas E. Merchant, Andrew M. Davidoff, Matthew J. Krasin, Barry L. Shulkin, Victor M. Santana, Wayne Lee Furman
Summary: This retrospective study aimed to identify predictors of metastatic site failure in high-risk neuroblastoma patients. The study found that improvements in systemic therapy influenced the patterns and type of metastatic site failure.
CLINICAL AND TRANSLATIONAL RADIATION ONCOLOGY
(2022)
Article
Biochemistry & Molecular Biology
Anniina Tervi, Nella Junna, Martin Broberg, Samuel E. Jones, Satu Strausz, Hanna-Riikka Kreivi, Caroline A. Heckman, Hanna M. Ollila, FinnGen
Summary: Tuberculosis is a significant public health concern that causes over 1 million deaths worldwide each year. This study identified specific HLA alleles and lifestyle risk factors, such as smoking, that are associated with the risk of tuberculosis.
HUMAN MOLECULAR GENETICS
(2023)
Article
Multidisciplinary Sciences
Enyang He, Bowen Shi, Ziyu Liu, Kaili Chang, Hailan Zhao, Wei Zhao, Hualei Cui
Summary: The aim of this study is to characterize different patient populations in neuroblastoma. By classifying cases from multiple datasets into subgroups based on immune-related cell cycle genes, the authors identified two subtypes with distinct clinical features, immune levels, chromosomal instability, and prognosis. A 7-gene risk model was constructed and drug sensitivity was assessed. This study provides a better understanding of neuroblastoma heterogeneity.
SCIENTIFIC REPORTS
(2023)
Editorial Material
Oncology
Liron D. Grossmann, John M. Maris
Summary: This study focused on the impact of hemizygous deletion of chromosome 11q on the response to immunotherapy in high-risk neuroblastoma, and explored potential transcriptional and post-transcriptional pathways that could be therapeutically targeted with biomarkers.
MOLECULAR ONCOLOGY
(2021)
Article
Multidisciplinary Sciences
Mehul Gupta, Sunand Kannappan, Mohit Jain, David Douglass, Ravi Shah, Pinaki Bose, Aru Narendran
Summary: We identified and validated a 21-gene signature capable of predicting risk of mortality in patients with neuroblastoma. This signature remained independent of known clinicopathological variables and improved prognostic performance when combined with these variables. The identified signature is a robust independent predictor of survival outcomes in neuroblastoma patients.
SCIENTIFIC REPORTS
(2023)
Article
Computer Science, Artificial Intelligence
Roohollah Shirani Faradonbeh, Will Vaisey, Mostafa Sharifzadeh, Jian Zhou
Summary: This study proposes comprehensible and practical classifiers for rockburst risk level appraisal by hybridizing K-means clustering with gene expression programming, logistic regression, and classification and regression tree. The classifiers' performance evaluation showed robustness and high classification capability. MatLab codes were also provided for implementing the model in practice.
NEURAL COMPUTING & APPLICATIONS
(2023)
Article
Mathematics
Milan Randelovic, Aleksandar Aleksic, Radovan Radovanovic, Vladica Stojanovic, Milan Cabarkapa, Dragan Randelovic
Summary: In this paper, a multidisciplinary-applicable aggregated model that combines traditional techniques and machine learning algorithms has been proposed and verified. The model aims to improve the results of solving multicriteria decision problems by taking advantage of both approaches. It uses feature selection methodology to increase model accuracy and has been evaluated using student grades from a specific university.
Article
Multidisciplinary Sciences
Song Zhai, Hong Zhang, Devan Mehrotra, Judong Shen
Summary: This article introduces a pharmacogenomics-specific polygenic risk score (PRS) method that can improve drug response prediction and patient stratification. By simultaneously modeling both the prognostic and predictive effects of genetic variants, the proposed approach outperforms traditional disease PRS methods.
NATURE COMMUNICATIONS
(2022)
Article
Cell Biology
Jinyang Cai, Sheeba Jacob, Richard Kurupi, Krista M. Dalton, Colin Coon, Patricia Greninger, Regina K. Egan, Giovanna T. Stein, Ellen Murchie, Joseph McClanaghan, Yuta Adachi, Kentaro Hirade, Mikhail Dozmorov, John Glod, Sosipatros A. Boikos, Hiromichi Ebi, Huaixiang Hao, Giordano Caponigro, Cyril H. Benes, Anthony C. Faber
Summary: Reoccurring/high-risk neuroblastoma (NB) tumors have non-RAS/RAF mutations along the MAPK signaling pathway, indicating the importance of MEK/ERK activation for their survival. However, MEK inhibitors are unlikely to be effective in NB based on preclinical data and have dose-limiting toxicities. In this study, the allosteric SHP2 inhibitor SHP099 demonstrated high sensitivity in NB models, especially those with low expression of neurofibromin 1 (NF1), a RAS GTPase activation protein (GAP). NF1 expression is lower in advanced and relapsed NB, and NF1 loss is common in high-risk NB tumors. SHP2 inhibition consistently blocked tumor growth in high-risk NB mouse models, revealing a new drug target for relapsed NB.
Article
Medicine, General & Internal
Skye Balyasny, Sang Mee Lee, Ami V. Desai, Samuel L. Volchenboum, Arlene Naranjo, Julie R. Park, Wendy B. London, Susan L. Cohn, Mark A. Applebaum
Summary: This study investigated the association between participation in clinical trials and improved survival among children with neuroblastoma. The results showed that participation in clinical trials was associated with higher overall survival in patients with intermediate-risk neuroblastoma, but not in those with high-risk neuroblastoma. Close to 44% of patients in this large cohort were enrolled in clinical trials, indicating a significant rate of participation in such studies.